Interacciones de Digoxina

Digoxina (Lanoxin, Digitek), glucósido digitálico, tiene 373 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 31; moderadas: 281; leves: 42; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 19. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (31)

  • Ácido etacrínicodiurético de asaGrave

    These generally have fallen into two categories: (1) patients with severe myocardial disease who have been receiving digitalis and presumably developed acute hypokalemia with fatal arrhythmia; (2) patients with severely decompensated hepatic cirrhosis with ascites, with or without accompanying encephalopathy, who were in electrolyte imbalance and died because… (etiqueta de Ácido etacrínico, Advertencias)

  • AmiodaronaantiarrítmicoGrave

    Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (etiqueta de Amiodarona, Advertencias y precauciones)

  • AsenapinaantipsicóticoGrave

    The use of SAPHRIS should be avoided in combination with other drugs known to prolong QTc including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and antibiotics (e.g., gatifloxacin, moxifloxacin). (etiqueta de Asenapina, Advertencias y precauciones)

  • AtazanavirantirretroviralGrave

    Drug Class Drugs within class that are contraindicated with REYATAZ Alpha 1-adrenoreceptor antagonist Alfuzosin Anticonvulsants Carbamazepine, phenobarbital, phenytoin Antiarrhythmics Amiodarone (with ritonavir), quinidine (with ritonavir) Antimycobacterials Rifampin Antineoplastics Apalutamide, encorafenib, irinotecan, ivosidenib Antipsychotics Lurasidone (with… (etiqueta de Atazanavir, Contraindicaciones)

  • Citrato férricoquelante de fosfatoGrave

    Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (etiqueta de Citrato férrico, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoGrave

    Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. (etiqueta de Claritromicina, Interacciones medicamentosas)

  • • Arrhythmias with Concomitant Digoxin Use: Avoid use of Calcium Chloride Injection in patients receiving digoxin. (etiqueta de Cloruro de calcio, Advertencias y precauciones)

  • DisopiramidaantiarrítmicoGrave

    Considering the known proarrhythmic properties of Norpace or Norpace CR and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of Norpace or Norpace CR as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. (etiqueta de Disopiramida, Advertencia en recuadro)

  • DofetilidaantiarrítmicoGrave

    NA – Not available/reported 7.3 Pharmacodynamic Drug Interactions Antiarrhythmics Dofetilide Concomitant administration with digoxin was associated with a higher rate of torsades de pointes . (etiqueta de Digoxina, Interacciones medicamentosas)

  • DronedaronaantiarrítmicoGrave

    Digoxin In the ANDROMEDA (patients with recently decompensated heart failure) and PALLAS (patients with permanent AF) trials baseline use of digoxin was associated with an increased risk of arrhythmic or sudden death in dronedarone-treated patients compared to placebo. (etiqueta de Dronedarona, Interacciones medicamentosas)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaGrave

    Thiazide-induced electrolyte disturbances, i.e. hypokalemia, hypomagnesemia, increase the risk of digoxin toxicity, which may lead to fatal arrhythmic events (see Precautions ). (etiqueta de Espironolactona e hidroclorotiazida, Interacciones medicamentosas)

  • FlecainidaantiarrítmicoGrave

    Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (etiqueta de Flecainida, Advertencia en recuadro)

  • FosamprenavirantirretroviralGrave

    Fosamprenavir calcium is contraindicated when coadministered with the following drugs: Alpha 1-adrenoreceptor antagonist: Alfuzosin Antiarrhythmics: Flecainide (with ritonavir ), propafenone (with ritonavir ) Antimycobacterial: Rifampin Antipsychotic: Lurasidone (with ritonavir ), pimozide Ergot derivatives: Dihydroergotamine, ergonovine, ergotamine, methylergonovine… (etiqueta de Fosamprenavir, Contraindicaciones)

  • FosfomicinaantibióticoGrave

    Avoid co-administration of CONTEPO with drugs known to prolong the QT interval, such as class IA or class III antiarrhythmic medications, tricyclic antidepressants, macrolides, and antipsychotics [see Warnings and Precautions ( 5.2 )] . (etiqueta de Fosfomicina, Interacciones medicamentosas)

  • Administration of Calcium Gluconate Injection should be avoided in patients receiving cardiac glycosides. (etiqueta de Gluconato de calcio, Advertencias y precauciones)

  • Hierba de San Juan (hipérico)Plantas medicinales y suplementosGrave

    La hierba de San Juan (hipérico) puede debilitar estos medicamentos al acelerar su descomposición, lo que puede significar rechazo del órgano, coágulos o pérdida de efecto. (NCCIH, St. John's Wort)

  • Itraconazolantifúngico azólicoGrave

    Antiarrhythmics Disopyramide Dofetilide Dronedarone Quinidine Contraindicated during and 2 weeks after TOLSURA treatment. (etiqueta de Itraconazol, Interacciones medicamentosas)

  • Lapatinibinhibidor de la glicoproteína PGrave

    These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes, and cumulative high-dose anthracycline therapy. (etiqueta de Lapatinib, Advertencias y precauciones)

  • Coadministration of amiodarone with ledipasvir and sofosbuvir is not recommended; if coadministration is required, cardiac monitoring is recommended [see Warnings and Precautions (5.2) , Adverse Reactions (6.2) ]. digoxin ↑ digoxin Coadministration of ledipasvir and sofosbuvir with digoxin may increase the concentration of digoxin. (etiqueta de Ledipasvir y sofosbuvir, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralGrave

    Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin… (etiqueta de Lopinavir y ritonavir, Contraindicaciones)

  • MexiletinaantiarrítmicoGrave

    Considering the known proarrhythmic properties of mexiletine and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of mexiletine as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmia. (etiqueta de Mexiletina, Advertencia en recuadro)

  • MilnacipránIRSNGrave

    Avoid co-administration of milnacipran hydrochloride and intravenous digoxin [see Warnings and Precautions ( 5.3 , 5.4 )] . (etiqueta de Milnaciprán, Interacciones medicamentosas)

  • MoxifloxacinofluoroquinolonaGrave

    Therefore, moxifloxacin should be avoided with Class IA and Class III antiarrhythmics [see Warnings and Precautions ( 5.6 ), Nonclinical Toxicology ( 13.2 ), and Patient Counseling Information ( 17 )]. (etiqueta de Moxifloxacino, Interacciones medicamentosas)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoGrave

    Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine extended-release tablet, it is recommended that digoxin levels be monitored when initiating, adjusting and discontinuing nifedipine extended-release tablet to avoid possible over- or under-digitalization. (etiqueta de Nifedipino, Interacciones medicamentosas)

  • …concentrations are associated with serious and/or life-threatening reactions [see Drug Interactions (7.3) ] : • Alpha 1-adrenoreceptor antagonist: alfuzosin • Antianginal: ranolazine • Antiarrhythmic: amiodarone, dronedarone, flecainide, propafenone, quinidine • Anti-gout: colchicine (in patients with renal and/or hepatic impairment [see Table 2 , Drug Interactions… (etiqueta de Nirmatrelvir y ritonavir, Contraindicaciones)

  • ProcainamidaantiarrítmicoGrave

    Considering the known proarrhythmic properties of procainamide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of procainamide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. (etiqueta de Procainamida, Advertencia en recuadro)

  • PropafenonaantiarrítmicoGrave

    • The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) or other antiarrhythmic drugs is uncertain, but at present, it is prudent to consider any IC antiarrhythmic to have a significant proarrhythmic risk in patients with structural heart disease. (etiqueta de Propafenona, Advertencia en recuadro)

  • QuinidinaantiarrítmicoGrave

    Proarrhythmic effects Like many other drugs (including all other Class Ia antiarrhythmics), quinidine prolongs the QT c interval, and this can lead to torsades de pointes , a life-threatening ventricular arrhythmia (see OVERDOSAGE ). (etiqueta de Quinidina, Advertencias)

  • RitonavirantirretroviralGrave

    WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (etiqueta de Ritonavir, Advertencia en recuadro)

  • Coadministration of amiodarone with VOSEVI is not recommended; if coadministration is required, cardiac monitoring is recommended [see Warnings and Precautions (5.3) ]. digoxin ↑ digoxin Therapeutic concentration monitoring of digoxin is recommended when coadministered with VOSEVI. (etiqueta de Sofosbuvir y velpatasvir, Interacciones medicamentosas)

  • Vardenafiloinhibidor de la PDE5Grave

    QT Prolongation : Patients with congenital QT syndrome or taking class IA or III antiarrhythmics should avoid using vardenafil hydrochloride tablets. (etiqueta de Vardenafilo, Advertencias y precauciones)

Interacciones moderadas (281)

  • AcarbosaantidiabéticoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • AcebutololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Acetato de calcioquelante de fosfatoModerada

    Hypercalcemia may aggravate digitalis toxicity. (etiqueta de Acetato de calcio, Advertencias y precauciones)

  • Acetazolamidainhibidor de la anhidrasa carbónicaModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Ácido mefenámicoAINEModerada

    Digoxin Clinical Impact: The concomitant use of mefenamic acid with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (etiqueta de Ácido mefenámico, Interacciones medicamentosas)

  • Ácido zoledrónicobisfosfonatoModerada

    In patients with renal impairment, the exposure to concomitant medications that are primarily renally excreted (e.g., digoxin) may increase. (etiqueta de Ácido zoledrónico, Interacciones medicamentosas)

  • AdrenalinasimpaticomiméticoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • AlprazolambenzodiazepinaModerada

    …Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Amiloridadiurético ahorrador de potasioModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Anfepramonaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Anfetaminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Anfetamina y dexanfetaminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Anfotericina BantifúngicoModerada

    Digitalis Glycosides Concurrent use may induce hypokalemia and may potentiate digitalis toxicity. (etiqueta de Anfotericina B, Interacciones medicamentosas)

  • Antiácidos (Tums, Maalox, Mylanta)Productos sin recetaModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Arformoterolagonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Articaína y adrenalinaanestésico localModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • AtenololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Atenolol y clortalidonabetabloqueanteModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • AtorvastatinaestatinaModerada

    • Digoxin: May increase digoxin plasma levels; monitor patients appropriately ( 7.3 ). (etiqueta de Atorvastatina, Interacciones medicamentosas)

  • Azelastina y fluticasonaantihistamínicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Azitromicinaantibiótico macrólidoModerada

    …Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations… (etiqueta de Digoxina, Interacciones medicamentosas)

  • BeclometasonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECAModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Benzfetaminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • BetametasonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • BetaxololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Bicarbonato de sodioantiácidoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Table 4 Drug Interactions with BIXLENVO Concomitant Drug Class: Drug Name Effect on Concentration ↑ = Increase, ↓ = Decrease Clinical Comment Antiarrhythmics: digoxin dofetilide ↑ digoxin ↑ dofetilide Use digoxin with caution and monitor digoxin therapeutic concentration. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

  • BisoprololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Brimonidinaagonista alfa-adrenérgicoModerada

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (etiqueta de Brimonidina, Interacciones medicamentosas)

  • Brimonidina y timololagonista alfa-adrenérgicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • BudesonidacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Budesonida y formoterolcorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Bumetanidadiurético de asaModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Bupivacaína y adrenalinaanestésico localModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • BuprenorfinaopioideModerada

    …in clinical decisions when prescribing BELBUCA to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia [see Dosage and Administration (2.4) , Adverse Reactions (6.1) , Clinical Pharmacology… (etiqueta de Buprenorfina, Advertencias y precauciones)

  • Consider these observations in clinical decisions when prescribing buprenorphine and naloxone sublingual tablets to patients with risk factors such as hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia. (etiqueta de Buprenorfina y naloxona, Advertencias y precauciones)

  • BupropiónantidepresivoModerada

    Drugs Metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide). (etiqueta de Bupropión, Interacciones medicamentosas)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Calcitriolanálogo de la vitamina DModerada

    Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias (see PRECAUTIONS: General ). (etiqueta de Calcitriol, Interacciones medicamentosas)

  • Canagliflozinainhibidor de SGLT2Moderada

    Digoxin Clinical Impact: Canagliflozin increases digoxin exposure [see Clinical Pharmacology (12.3) ] . (etiqueta de Canagliflozina, Interacciones medicamentosas)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Cannabidiol (con receta)anticonvulsivoModerada

    Increases in exposure of other orally administered P‑gp substrates (e.g., sirolimus, tacrolimus, digoxin) may be observed when concomitantly used with EPIDIOLEX. (etiqueta de Cannabidiol (con receta), Interacciones medicamentosas)

  • CarvedilolbetabloqueanteModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • CelecoxibAINEModerada

    Digoxin Clinical Impact: The concomitant use of Celecoxib with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (etiqueta de Celecoxib, Interacciones medicamentosas)

  • CiclesonidacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    …25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating… (etiqueta de Digoxina, Interacciones medicamentosas)

  • CiprofloxacinofluoroquinolonaModerada

    …syndrome, uncorrected electrolyte imbalance, such as hypokalemia or hypomagnesemia and cardiac disease, such as heart failure, myocardial infarction, or bradycardia), and patients receiving Class IA antiarrhythmic agents (quinidine, procainamide), or Class III antiarrhythmic agents (amiodarone, sotalol), tricyclic antidepressants, macrolides, and antipsychotics. (etiqueta de Ciprofloxacino, Advertencias y precauciones)

  • CitalopramISRSModerada

    Such drugs include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (etiqueta de Citalopram, Advertencias y precauciones)

  • CitarabinaantimetabolitoModerada

    Drug Interactions Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyldigoxin and chemotherapy regimens containing cyclophosphamide, vincristine and prednisone with or without cytarabine injection or procarbazine. (etiqueta de Citarabina, Interacciones medicamentosas)

  • ClobetasolcorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Clomipraminaantidepresivo tricíclicoModerada

    Because clomipramine hydrochloride capsules are highly bound to serum protein, the administration of clomipramine hydrochloride capsules to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects. (etiqueta de Clomipramina, Interacciones medicamentosas)

  • Clonidinaagonista alfa-adrenérgicoModerada

    Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (etiqueta de Clonidina, Interacciones medicamentosas)

  • Clorotiazidadiurético tiazídicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • ClozapinaantipsicóticoModerada

    …droperidol, pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmic medications (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus). (etiqueta de Clozapina, Advertencias y precauciones)

  • Colestipolsecuestrador de ácidos biliaresModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Colestiraminasecuestrador de ácidos biliaresModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Dapagliflozinainhibidor de SGLT2Moderada

    …mg ↔ ↔ Bumetanide (1 mg) 10 mg once daily for 7 days ↑13% [↓2%, ↑31%] ↑13% [↓1%, ↑30%] Valsartan (320 mg) 20 mg ↓6% [↓24%, ↑16%] ↑5% [↓15%, ↑29%] Simvastatin (40 mg) 20 mg ↔ ↑19% Digoxin (0.25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ Warfarin (25 mg) 20 mg loading dose then 10 mg once daily for 7 days ↔ ↔ ↔ = no change (geometric mean ratio… (etiqueta de Dapagliflozina, Interacciones medicamentosas)

  • Dapagliflozina y metforminainhibidor de SGLT2Moderada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • DarifenacinaanticolinérgicoModerada

    Routine therapeutic drug monitoring for digoxin should be continued [see Clinical Pharmacology (12.3)] . (etiqueta de Darifenacina, Interacciones medicamentosas)

  • DarunavirantirretroviralModerada

    The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect. (etiqueta de Darunavir, Interacciones medicamentosas)

  • Darunavir y cobicistatantirretroviralModerada

    Other antiarrhythmics e.g. amiodarone, disopyramide, flecainide, lidocaine (systemic), mexiletine, propafenone, quinidine ↑ antiarrhythmics Clinical monitoring is recommended upon co-administration with antiarrhythmics. digoxin ↑ digoxin When co-administering with digoxin, titrate the digoxin dose and monitor digoxin concentrations. (etiqueta de Darunavir y cobicistat, Interacciones medicamentosas)

  • DasatinibModerada

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (etiqueta de Dasatinib, Advertencias y precauciones)

  • DeflazacortcorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • DesonidacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • DexametasonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Dexanfetaminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Dexlansoprazolinhibidor de la bomba de protonesModerada

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (etiqueta de Dexlansoprazol, Advertencias y precauciones)

  • Dexmetilfenidatoestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Digoxin: Increased digoxin substrate plasma concentration may occur. (etiqueta de Dextrometorfano y quinidina, Interacciones medicamentosas)

  • DicicloverinaanticolinérgicoModerada

    Effect on Absorption of Other Drugs Anticholinergic agents may affect gastrointestinal absorption of various drugs by affecting on gastrointestinal motility, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentration may result. (etiqueta de Dicicloverina, Interacciones medicamentosas)

  • DiclofenacoAINEModerada

    …Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant… (etiqueta de Digoxina, Interacciones medicamentosas)

  • …Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant… (etiqueta de Digoxina, Interacciones medicamentosas)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Diltiazembloqueador de los canales de calcioModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • DobutaminasimpaticomiméticoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Dorzolamida y timololinhibidor de la anhidrasa carbónicaModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Doxercalciferolanálogo de la vitamina DModerada

    Digitalis Toxicity: Hypercalcemia increases the risk of digitalis toxicity. (etiqueta de Doxercalciferol, Advertencias y precauciones)

  • Droperidolantagonista de la dopaminaModerada

    …development of prolonged QT syndrome, such as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS,… (etiqueta de Droperidol, Advertencias)

  • DroxidopasimpaticomiméticoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Dutasteridainhibidor de la 5-alfa reductasaModerada

    Digoxin Dutasteride capsules do not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg/day for 3 weeks [see Clinical Pharmacology (12.3) ]. (etiqueta de Dutasterida, Interacciones medicamentosas)

  • Dutasterida y tamsulosinainhibidor de la 5-alfa reductasaModerada

    Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3) ]. (etiqueta de Dutasterida y tamsulosina, Interacciones medicamentosas)

  • EfedrinasimpaticomiméticoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Transporters Concomitant use of ivacaftor or tezacaftor/ivacaftor with digoxin, a sensitive P-gp substrate, increased digoxin AUC by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Interacciones medicamentosas)

  • Antiarrhythmics: e.g., amiodarone bepridil digoxin Indicates that a drug-drug interaction trial was conducted. disopyramide flecainide systemic lidocaine mexiletine propafenone quinidine ↑ antiarrhythmics ↑ digoxin Caution is warranted and therapeutic concentration monitoring, if available, is recommended for antiarrhythmics when coadministered with GENVOYA. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

  • Empagliflozina y metforminainhibidor de SGLT2Moderada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Enalapril e hidroclorotiazidainhibidor de la ECAModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Epoprostenolanálogo de prostaglandinaModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Ergotamina y cafeínaalcaloide ergóticoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • EribulinaModerada

    ECG monitoring is recommended if therapy is initiated in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics, and electrolyte abnormalities. (etiqueta de Eribulina, Advertencias y precauciones)

  • Eritromicinaantibiótico macrólidoModerada

    Erythromycin should be avoided in patients with known prolongation of the QT interval, patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etiqueta de Eritromicina, Advertencias)

  • EsmololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Esomeprazolinhibidor de la bomba de protonesModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Espironolactonaantagonista de la aldosteronaModerada

    …Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • EtodolacoAINEModerada

    Cyclosporine, Digoxin, Methotrexate Etodolac, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity. (etiqueta de Etodolaco, Interacciones medicamentosas)

  • EtravirinaantirretroviralModerada

    Other agents Antiarrhythmics : digoxin ↔ etravirine ↑ digoxin For patients who are initiating a combination of Etravirine and digoxin, the lowest dose of digoxin should initially be prescribed. (etiqueta de Etravirina, Interacciones medicamentosas)

  • Exenatidaagonista del receptor de GLP-1Moderada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Ezetimiba y simvastatinaestatinaModerada

    Digoxin : During VYTORIN initiation, monitor digoxin levels. (etiqueta de Ezetimiba y simvastatina, Interacciones medicamentosas)

  • FamciclovirantiviralModerada

    Potential for Famciclovir to Affect Other Drugs The steady-state pharmacokinetics of digoxin were not altered by concomitant administration of multiple doses of famciclovir (500 mg three times daily). (etiqueta de Famciclovir, Interacciones medicamentosas)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Fendimetrazinaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • FenilefrinadescongestionanteModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • FenitoínaanticonvulsivoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • FenoprofenoAINEModerada

    Digoxin Clinical Impact: The concomitant use of fenoprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (etiqueta de Fenoprofeno, Interacciones medicamentosas)

  • FentaniloopioideModerada

    …as: 1) clinically significant bradycardia (less than 50 bpm), 2) any clinically significant cardiac disease, including baseline prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte… (etiqueta de Fentanilo, Advertencias y precauciones)

  • Fenterminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Flibanserinadepresor del SNCModerada

    Digoxin or Other P-glycoprotein Substrates Examples Digoxin, sirolimus Clinical Implications The concomitant use of ADDYI with digoxin, a drug that is transported by P-glycoprotein (P-gp), increases the digoxin concentration [see Clinical Pharmacology (12.3) ] . (etiqueta de Flibanserina, Interacciones medicamentosas)

  • FludrocortisonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • FlunisolidacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • FluocinonidacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • FluoxetinaISRSModerada

    Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. (etiqueta de Fluoxetina, Interacciones medicamentosas)

  • FlurbiprofenoAINEModerada

    Digoxin Clinical Impact: The concomitant use of flurbiprofen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin [ see Clinical Pharmacology (12.3) ]. (etiqueta de Flurbiprofeno, Interacciones medicamentosas)

  • FluticasonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Fluticasona y salmeterolcorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Formoterolagonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • FoscarnetantiviralModerada

    …prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic antidepressants, and certain macrolides and fluoroquinolones. (etiqueta de Foscarnet, Interacciones medicamentosas)

  • FosfenitoínaanticonvulsivoModerada

    …concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil Other Albendazole (decreases active metabolite), chlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine 7.3 Hyperammonemia with Concomitant Use of Valproate Concomitant administration of phenytoin and valproate… (etiqueta de Fosfenitoína, Interacciones medicamentosas)

  • Fosinoprilinhibidor de la ECAModerada

    In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs. (etiqueta de Fosinopril, Interacciones medicamentosas)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Furosemidadiurético de asaModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Glibenclamida y metforminasulfonilureaModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • GlicopirronioanticolinérgicoModerada

    Other Anticholinergic Drugs There is potential for an additive interaction between glycopyrrolate and concomitantly used anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, anti­-spasmodics, amantadine) resulting in increased anticholinergic adverse reactions. (etiqueta de Glicopirronio, Interacciones medicamentosas)

  • Glipizida y metforminasulfonilureaModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • HalobetasolcorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • HidrocortisonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTModerada

    Digoxin Concomitant PLAQUENIL and digoxin therapy may result in increased serum digoxin levels. (etiqueta de Hidroxicloroquina, Interacciones medicamentosas)

  • IbuprofenoAINEModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • IbutilidaantiarrítmicoModerada

    Digoxin: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive digoxin levels. (etiqueta de Ibutilida, Interacciones medicamentosas)

  • IloperidonaantipsicóticoModerada

    …FANAPT should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to… (etiqueta de Iloperidona, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • IndometacinaAINEModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Ipratropio y salbutamolanticolinérgicoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Isoprenalina (isoproterenol)agonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • IvabradinaModerada

    Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel Blocker Ivabradine can increase the risk of bradycardia. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Ivacaftorinhibidor de CYP3A4Moderada

    Co-administration with digoxin, a sensitive P-gp substrate, increased digoxin exposure by 1.3-fold, consistent with weak inhibition of P-gp by ivacaftor. (etiqueta de Ivacaftor, Interacciones medicamentosas)

  • Ketoconazolantifúngico azólicoModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • KetorolacoAINEModerada

    Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. (etiqueta de Ketorolaco, Interacciones medicamentosas)

  • LabetalolbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Lansoprazolinhibidor de la bomba de protonesModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • LenacapavirantirretroviralModerada

    Clinical Comment Antiarrhythmics: digoxin ↑ digoxin Use with caution and monitor digoxin therapeutic concentration. (etiqueta de Lenacapavir, Interacciones medicamentosas)

  • LenalidomidaModerada

    • Digoxin: Monitor digoxin plasma levels periodically due to increased C max and AUC with concomitant REVLIMID therapy ( 7.1 ). (etiqueta de Lenalidomida, Interacciones medicamentosas)

  • LevetiracetamanticonvulsivoModerada

    Digoxin Levetiracetam (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day. (etiqueta de Levetiracetam, Interacciones medicamentosas)

  • LevofloxacinofluoroquinolonaModerada

    Levofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. (etiqueta de Levofloxacino, Advertencias y precauciones)

  • Levosalbutamolagonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Levotiroxinahormona tiroideaModerada

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (etiqueta de Digoxina, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (etiqueta de Digoxina, Advertencias y precauciones)

  • Lidocaína y adrenalinaanestésico localModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Linagliptina y metforminainhibidor de la DPP-4Moderada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Liotironinahormona tiroideaModerada

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (etiqueta de Digoxina, Advertencias y precauciones)

  • Lisdexanfetaminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • LomitapidaModerada

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etiqueta de Lomitapida, Interacciones medicamentosas)

  • Loperamidafármaco que prolonga el intervalo QTModerada

    …combination with others drugs or herbal products that are known to prolong the QT interval, including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, antipsychotics (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), or any other drug known to prolong the QT interval… (etiqueta de Loperamida, Advertencias)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • MetadonaopioideModerada

    Examples: Drugs known to have potential to prolong QT interval: Class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers. (etiqueta de Metadona, Interacciones medicamentosas)

  • Metanfetaminaestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • MetforminabiguanidaModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Metilfenidatoestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • MetilprednisolonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Metimazolfármaco antitiroideoModerada

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (etiqueta de Digoxina, Advertencias y precauciones)

  • Metoclopramidaantagonista de la dopaminaModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Metolazonadiurético tiazídicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • MetoprololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Midodrinaagonista alfa-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • MiglitolantidiabéticoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • MometasonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • NadololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Naltrexona y bupropiónantagonista opioideModerada

    Digoxin: May decrease plasma digoxin levels. (etiqueta de Naltrexona y bupropión, Interacciones medicamentosas)

  • NaproxenoAINEModerada

    Digoxin Clinical Impact: The concomitant use of naproxen with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin Intervention: During concomitant use of Naproxen Suspension and digoxin, monitor serum digoxin levels. (etiqueta de Naproxeno, Interacciones medicamentosas)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • NebivololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • NefazodonaantidepresivoModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • NeomicinaaminoglucósidoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • NevirapinaantirretroviralModerada

    Antiarrhythmics: Amiodarone, disopyramide, lidocaine Plasma concentrations may be decreased. (etiqueta de Nevirapina, Interacciones medicamentosas)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • OctreotidaModerada

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (etiqueta de Octreotida, Interacciones medicamentosas)

  • OfloxacinofluoroquinolonaModerada

    Ofloxacin should be avoided in patients with known prolongation of the QT interval, patients with uncorrected hypokalemia, and patients receiving Class IA (quinidine, procainamide), or Class III (amiodarone, sotalol) antiarrhythmic agents. (etiqueta de Ofloxacino, Precauciones)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution. (etiqueta de Olanzapina y fluoxetina, Interacciones medicamentosas)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Olopatadina y mometasonaantihistamínicoModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Omeprazolinhibidor de la bomba de protonesModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Omeprazol y bicarbonato de sodioinhibidor de la bomba de protonesModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • OxaliplatinoModerada

    Monitor electrocardiograms (ECG) in patients with congestive heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics [see Drug Interactions (7.1)] . (etiqueta de Oxaliplatino, Advertencias y precauciones)

  • OxaprozinaAINEModerada

    Digoxin Clinical Impact: The concomitant use of oxaprozin with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin. (etiqueta de Oxaprozina, Interacciones medicamentosas)

  • OximetazolinadescongestionanteModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • PaliperidonaantipsicóticoModerada

    …paliperidone should be avoided in combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to… (etiqueta de Paliperidona, Advertencias y precauciones)

  • Pantoprazolinhibidor de la bomba de protonesModerada

    For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (etiqueta de Pantoprazol, Advertencias y precauciones)

  • …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Paricalcitolanálogo de la vitamina DModerada

    Digitalis Toxicity: Risk increases with hypercalcemia. (etiqueta de Paricalcitol, Advertencias y precauciones)

  • PazopanibModerada

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (etiqueta de Pazopanib, Advertencias y precauciones)

  • PenicilaminaModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • PimavanserinaantipsicóticoModerada

    The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain… (etiqueta de Pimavanserina, Advertencias y precauciones)

  • PimozidaantipsicóticoModerada

    DRUG INTERACTIONS Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. (etiqueta de Pimozida, Interacciones medicamentosas)

  • PindololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Pioglitazona y metforminatiazolidinedionaModerada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • PiroxicamAINEModerada

    Digoxin: Concomitant use of Piroxicam Capsules can increase serum concentration and prolong half-life of digoxin. (etiqueta de Piroxicam, Interacciones medicamentosas)

  • PonesimodinmunosupresorModerada

    Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (etiqueta de Ponesimod, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoModerada

    Digoxin Monitor digoxin plasma concentrations ( 7.2 ) (etiqueta de Posaconazol, Interacciones medicamentosas)

  • PrednisolonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • PrednisonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Prilocaína y adrenalinaanestésico localModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • PrimaquinaantipalúdicoModerada

    P-gp Substrates Refer to the Prescribing Information for a P-gp substrate where minimal concentration changes may lead to serious adverse reactions (e.g., digoxin and dabigatran) for the recommended dosage modification and/or monitoring. (etiqueta de Primaquina, Interacciones medicamentosas)

  • Propiltiouracilofármaco antitiroideoModerada

    Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (etiqueta de Digoxina, Advertencias y precauciones)

  • PropranololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • PseudoefedrinadescongestionanteModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Quinapril e hidroclorotiazidainhibidor de la ECAModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • QuininaantipalúdicoModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Rabeprazolinhibidor de la bomba de protonesModerada

    Carvedilol 16% 14% Conivaptan 33% 43% Diltiazem 20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Drugs transported by P-gp (e.g., digoxin), or drugs metabolized by CYP2D6 (e.g., tricyclic antidepressants) may need reduced doses when used with ASPRUZYO Sprinkle. (etiqueta de Ranolazina, Interacciones medicamentosas)

  • RifampicinaantibióticoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    …itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins… (etiqueta de Rifapentina, Interacciones medicamentosas)

  • Rolapitantinhibidor de CYP2D6Moderada

    P-gp Substrates with a Narrow Therapeutic Index (e.g. digoxin) Clinical Impact: Increased plasma concentrations of P-gp substrates (e.g., digoxin) may result in potential adverse reactions [see Clinical Pharmacology (12.3) ]. (etiqueta de Rolapitant, Interacciones medicamentosas)

  • Ropivacaínaanestésico localModerada

    …anesthetics or agents structurally related to amide- type local anesthetics, since the toxic effects of these drugs are additive. [See Drug Interactions 7.0 ] Patients treated with class III antiarrhythmic drugs (e.g., amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive. [See Drug Interactions 7.0… (etiqueta de Ropivacaína, Advertencias y precauciones)

  • Salbutamolagonista beta-adrenérgicoModerada

    Digoxin Concentrations Decreased Acarbose, Activated Charcoal, Albuterol, Antacids, certain cancer chemotherapy or radiation therapy, Cholestyramine, Colestipol, Exenatide, Kaolin-pectin, Meals High in Bran, Metoclopramide, Miglitol, Neomycin, Penicillamine, Phenytoin, Rifampin, St. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Salmeterolagonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Saxagliptina y metforminainhibidor de la DPP-4Moderada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • SimvastatinaestatinaModerada

    Digoxin: During ZOCOR initiation, monitor digoxin levels. (etiqueta de Simvastatina, Interacciones medicamentosas)

  • Sitagliptina y metforminainhibidor de la DPP-4Moderada

    …to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen, Ketoconazole, Lansoprazole, Metformin, Omeprazole Measure serum digoxin concentrations before initiating concomitant drugs. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Solriamfetolestimulante del SNCModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • SorafenibModerada

    Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etiqueta de Sorafenib, Advertencias y precauciones)

  • SotalolbetabloqueanteModerada

    Sotalol Proarrhythmic events were more common in patients receiving sotalol and digoxin than on either alone; it is not clear whether this represents an interaction or is related to the presence of CHF, a known risk factor for proarrhythmia, in patients receiving digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • SucralfatoModerada

    Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (etiqueta de Sucralfato, Interacciones medicamentosas)

  • …15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • SulfasalazinasulfonamidaModerada

    Drug Interactions: Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine. (etiqueta de Sulfasalazina, Interacciones medicamentosas)

  • Sumatriptán y naproxenotriptánModerada

    Digoxin: Concomitant use with sumatriptan and naproxen sodium tablets can increase serum concentration and prolong half-life of digoxin. (etiqueta de Sumatriptán y naproxeno, Interacciones medicamentosas)

  • SunitinibModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Suvorexantsedante-hipnóticoModerada

    Digoxin: Monitor digoxin concentrations ( 7.3 ). (etiqueta de Suvorexant, Interacciones medicamentosas)

  • Suxametonio (succinilcolina)bloqueador neuromuscularModerada

    Hyperkalemia QUELICIN may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia in patients with electrolyte abnormalities and those who may have digitalis toxicity. (etiqueta de Suxametonio (succinilcolina), Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    …electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment in patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other products that lead to QT prolongation, and those with electrolyte disturbances (e.g., hypokalemia, hypocalcemia, or hypomagnesemia). (etiqueta de Tacrolimus, Advertencias y precauciones)

  • TamsulosinaalfabloqueanteModerada

    Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Tamsulosina, Interacciones medicamentosas)

  • Telmisartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    …20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    …20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    …20% NA Indomethacin 40% NA Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Terbutalinaagonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Teriparatidahormona tiroideaModerada

    Parathyroid Hormone Analog Teriparatide Sporadic case reports have suggested that hypercalcemia may predispose patients to digitalis toxicity. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Tetrabenazinainhibidor de VMAT2Moderada

    …are known to prolong QTc, including antipsychotic medications (e.g., chlorpromazine, haloperidol, thioridazine, ziprasidone), antibiotics (e.g., moxifloxacin), Class 1A (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic medications or any other medications known to prolong the QTc interval [see Drug Interactions ( 7.5 )]. (etiqueta de Tetrabenazina, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioModerada

    …Mirabegron 29% 27% Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • TimololbetabloqueanteModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • TolvaptánModerada

    …Nefazodone 27% 15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Torasemidadiurético de asaModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Toremifenomodulador selectivo de los receptores de estrógenosModerada

    Agents generally accepted to prolong QT interval include Class 1A (e.g., quinidine, procainamide, disopyramide) and Class III (e.g., amiodarone, sotalol, ibutilide, dofetilide) antiarrhythmics; certain antipsychotics (e.g., thioridazine, haloperidol); certain antidepressants (e.g., venlafaxine, amitriptyline); certain antibiotics (e.g., erythromycin, clarithromycin,… (etiqueta de Toremifeno, Interacciones medicamentosas)

  • TramadolopioideModerada

    Digoxin Clinical Impact: Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity. (etiqueta de Tramadol, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideModerada

    Digoxin Clinical Impact: Post-marketing surveillance of tramadol has revealed rare reports of digoxin toxicity. (etiqueta de Tramadol y paracetamol, Interacciones medicamentosas)

  • TrazodonaantidepresivoModerada

    Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels ( 7 ). (etiqueta de Trazodona, Interacciones medicamentosas)

  • TriamcinolonacorticosteroideModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • TrimetoprimaantibióticoModerada

    …15% Nifedipine 45% NA Propantheline 24% 24% Quinine NA 33% Rabeprazole 29% 19% Saquinavir 27% 49% Spironolactone 25% NA Telmisartan 20 to 49% NA Ticagrelor 31% 28% Tolvaptan 30% 20% Trimethoprim 22 to 28% NA Digoxin Concentrations Increased, but Magnitude is Unclear Alprazolam, Azithromycin, Cyclosporine, Diclofenac, Diphenoxylate, Epoprostenol, Esomeprazole, Ibuprofen,… (etiqueta de Digoxina, Interacciones medicamentosas)

  • Umeclidinio y vilanterolanticolinérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Valbenazinainhibidor de VMAT2Moderada

    Digoxin Clinical Implication: Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp) [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Valbenazina, Interacciones medicamentosas)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioModerada

    Beta-adrenergic Blockers and Calcium Channel Blockers Additive effects on AV node conduction can result in complete heart block. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Vibegrónagonista beta-adrenérgicoModerada

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etiqueta de Digoxina, Interacciones medicamentosas)

  • VilazodonaISRSModerada

    Concomitant use of VIIBRYD increased digoxin concentrations [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Vilazodona, Interacciones medicamentosas)

Menciones leves (42)

  • AcitretinaretinoideLeve

    Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, digoxin, or glyburide. (etiqueta de Acitretina, Interacciones medicamentosas)

  • AdenosinaantiarrítmicoLeve

    Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (etiqueta de Adenosina, Interacciones medicamentosas)

  • Amitriptilinaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (etiqueta de Amitriptilina, Interacciones medicamentosas)

  • Amoxapinaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (etiqueta de Amoxapina, Interacciones medicamentosas)

  • Atracuriobloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Buspironafármaco serotoninérgicoLeve

    The patient was also chronically receiving phenytoin, phenobarbital, digoxin, and Synthroid®. (etiqueta de Buspirona, Interacciones medicamentosas)

  • Captoprilinhibidor de la ECALeve

    Cardiac Glycosides In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-digoxin interaction could be found. (etiqueta de Captopril, Interacciones medicamentosas)

  • Sixteen (16) drugs tested did not show an in vitro interaction with LOKELMA (allopurinol, apixaban, aspirin, captopril, cyclosporine, digoxin, ethinyl estradiol, lisinopril, magnesium, metformin, phenytoin, prednisone, propranolol, quinapril, spironolactone and ticagrelor). (etiqueta de Ciclosilicato de sodio y zirconio, Interacciones medicamentosas)

  • Cisatracuriobloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Desipraminaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). (etiqueta de Desipramina, Interacciones medicamentosas)

  • Enalaprilatoinhibidor de la ECALeve

    Other Cardiovascular Agents Enalaprilat injection, USP has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions. (etiqueta de Enalaprilato, Interacciones medicamentosas)

  • FingolimodinmunosupresorLeve

    Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (etiqueta de Fingolimod, Interacciones medicamentosas)

  • FondaparinuxanticoagulanteLeve

    In addition, fondaparinux sodium neither influenced the pharmacodynamics of warfarin sodium, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state. (etiqueta de Fondaparinux, Interacciones medicamentosas)

  • GinsengPlantas medicinales y suplementosLeve

    Some traditional Chinese and Ayurvedic medicine substances like Chan Su, Siberian Ginseng, Asian Ginseng, Ashwagandha or Dashen, can cause similar interference. (etiqueta de Digoxina, Interacciones medicamentosas)

  • HaloperidolantipsicóticoLeve

    Examples include (but are not limited to): Class 1A antiarrhythmics (e.g., procainamide, quinidine, disopyramide); Class 3 antiarrhythmics (e.g., amiodarone, sotalol); and other drugs such as citalopram, erythromycin, levofloxacin, methadone, and ziprasidone. (etiqueta de Haloperidol, Interacciones medicamentosas)

  • HeparinaanticoagulanteLeve

    Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (etiqueta de Heparina, Interacciones medicamentosas)

  • HidroxizinaantihistamínicoLeve

    These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin);… (etiqueta de Hidroxizina, Precauciones)

  • Imipraminaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (etiqueta de Imipramina, Interacciones medicamentosas)

  • LamotriginaanticonvulsivoLeve

    Cardiac Rhythm and Conduction Abnormalities In vitro testing showed that lamotrigine exhibits Class IB antiarrhythmic activity at therapeutically relevant concentrations [see Clinical Pharmacology ( 12.2 )] . (etiqueta de Lamotrigina, Advertencias y precauciones)

  • Lorlatinibinductor de CYP3A4Leve

    • PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Milrinonainhibidor de la PDE3Leve

    Drug Interactions No untoward clinical manifestations have been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin,… (etiqueta de Milrinona, Interacciones medicamentosas)

  • Moexiprilinhibidor de la ECALeve

    Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (etiqueta de Moexipril, Interacciones medicamentosas)

  • Nortriptilinaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (etiqueta de Nortriptilina, Interacciones medicamentosas)

  • PentoxifilinametilxantinaLeve

    Pentoxifylline extended-release tablets have been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, and antiarrhythmics, without observed problems. (etiqueta de Pentoxifilina, Interacciones medicamentosas)

  • PerfenazinaantipsicóticoLeve

    Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (etiqueta de Perfenazina, Interacciones medicamentosas)

  • Piridostigminainhibidor de la colinesterasaLeve

    Aminoglycoside antibiotics, local and some general anesthetics, antiarrhythmic agents, and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all. (etiqueta de Piridostigmina, Interacciones medicamentosas)

  • Prasugrelantiagregante plaquetarioLeve

    Effient can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, digoxin, and drugs that elevate gastric pH, including proton pump inhibitors and H 2 blockers [see Clinical Pharmacology (12.3) ] . (etiqueta de Prasugrel, Interacciones medicamentosas)

  • PrazosinaalfabloqueanteLeve

    Drug Interactions Prazosin hydrochloride capsules have been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and… (etiqueta de Prazosina, Interacciones medicamentosas)

  • Protriptilinaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). (etiqueta de Protriptilina, Precauciones)

  • Raloxifenomodulador selectivo de los receptores de estrógenosLeve

    Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Raloxifeno, Interacciones medicamentosas)

  • RibavirinaantiviralLeve

    Drug Interactions Clinical studies of interactions of Ribavirin for Inhalation Solution, USP with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other antiviral agents, antibiotics or anti-metabolites, have not been conducted. (etiqueta de Ribavirina, Interacciones medicamentosas)

  • RisperidonaantipsicóticoLeve

    Digoxin Oral RISPERDAL (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. (etiqueta de Risperidona, Interacciones medicamentosas)

  • Rocuroniobloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • SilodosinaalfabloqueanteLeve

    Digoxin The effect of co‑administration of silodosin capsules and digoxin 0.25 mg/day for 7 days was evaluated in a clinical trial in 16 healthy males, aged 18 to 45 years. (etiqueta de Silodosina, Interacciones medicamentosas)

  • TerbinafinaantifúngicoLeve

    Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. (etiqueta de Terbinafina, Interacciones medicamentosas)

  • Tizanidinarelajante muscularLeve

    Moderate or Weak CYP1A2 Inhibitors Concomitant use of Zanaflex with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. (etiqueta de Tizanidina, Interacciones medicamentosas)

  • Toxina botulínica tipo Abloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Toxina incobotulínica Abloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Toxina onabotulínica Abloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Trimipraminaantidepresivo tricíclicoLeve

    The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). (etiqueta de Trimipramina, Interacciones medicamentosas)

  • Vecuroniobloqueador neuromuscularLeve

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (etiqueta de Digoxina, Interacciones medicamentosas)

  • Zileutóninhibidor de CYP1A2Leve

    Drug-drug interaction studies in healthy subjects have been conducted with zileuton immediate-release tablets and digoxin, phenytoin, sulfasalazine, and naproxen. (etiqueta de Zileutón, Interacciones medicamentosas)

Sin interacción significativa según la etiqueta (19)

  • DoxazosinaalfabloqueanteSin interacción

    In vitro data in human plasma indicate that Doxazosin has no effect on protein binding of digoxin, warfarin, phenytoin, or indomethacin. (etiqueta de Doxazosina, Interacciones medicamentosas)

  • Emtricitabina, rilpivirina y tenofovirantirretroviralSin interacción

    RPV did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin. (etiqueta de Emtricitabina, rilpivirina y tenofovir, Interacciones medicamentosas)

  • Finasteridainhibidor de la 5-alfa reductasaSin interacción

    Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. (etiqueta de Finasterida, Interacciones medicamentosas)

  • FluvoxaminaISRSSin interacción

    Digoxin: Administration of fluvoxamine maleate 100 mg daily for 18 days (N=8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. (etiqueta de Fluvoxamina, Interacciones medicamentosas)

  • KetoprofenoAINESin interacción

    Digoxin In a study in 12 patients with congestive heart failure where ketoprofen and digoxin were concomitantly administered, ketoprofen did not alter the serum levels of digoxin. (etiqueta de Ketoprofeno, Advertencias y precauciones)

  • Losartánantagonista de los receptores de la angiotensina II (ARA-II)Sin interacción

    Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. (etiqueta de Losartán, Interacciones medicamentosas)

  • LovastatinaestatinaSin interacción

    Digoxin In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations. (etiqueta de Lovastatina, Interacciones medicamentosas)

  • Montelukastantagonista de los receptores de leucotrienosSin interacción

    No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (etiqueta de Montelukast, Interacciones medicamentosas)

  • Perindoprilinhibidor de la ECASin interacción

    Digoxin A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with perindopril erbumine, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. (etiqueta de Perindopril, Interacciones medicamentosas)

  • Quinaprilinhibidor de la ECASin interacción

    Quinapril hydrochloride treatment did not affect the pharmacokinetics of digoxin. (etiqueta de Quinapril, Interacciones medicamentosas)

  • RilpivirinaantirretroviralSin interacción

    Rilpivirine did not have a clinically significant effect on the pharmacokinetics of digoxin or metformin. (etiqueta de Rilpivirina, Interacciones medicamentosas)

  • Ropinirolagonista de la dopaminaSin interacción

    Drug Interaction Studies Digoxin: Coadministration of ropinirole (2 mg 3 times daily) with digoxin (0.125 to 0.25 mg once daily) did not alter the steady-state pharmacokinetics of digoxin in 10 patients. (etiqueta de Ropinirol, Interacciones medicamentosas)

  • SertralinaISRSSin interacción

    Additionally, no dosage adjustment is required for diazepam, lithium, atenolol, tolbutamide, digoxin, and drugs metabolized by CYP3A4, when sertraline hydrochloride capsules is administered concomitantly [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Sertralina, Interacciones medicamentosas)

  • Sevelámeroquelante de fosfatoSin interacción

    Table 5: Sevelamer Drug Interactions Oral drugs for which sevelamer did not alter the pharmacokinetics when administered concomitantly Digoxin Enalapril Iron Metoprolol Warfarin Oral drugs that have demonstrated interaction with sevelamer and are to be dosed separately from sevelamer carbonate Dosing Recommendations Ciprofloxacin Take at least 2 hours before… (etiqueta de Sevelámero, Interacciones medicamentosas)

  • Tadalafiloinhibidor de la PDE5Sin interacción

    P-glycoprotein (e.g. Digoxin) — Coadministration of tadalafil (40 mg once per day) for 10 days did not have a significant effect on the steady-state pharmacokinetics of digoxin (0.25 mg/day) in healthy subjects. (etiqueta de Tadalafilo, Interacciones medicamentosas)

  • TiagabinaanticonvulsivoSin interacción

    Digoxin : Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin. (etiqueta de Tiagabina, Interacciones medicamentosas)

  • Trandolaprilinhibidor de la ECASin interacción

    Other No clinically significant pharmacokinetic interaction has been found between trandolaprilat and food, cimetidine, digoxin, or furosemide. (etiqueta de Trandolapril, Interacciones medicamentosas)

  • TrospioanticolinérgicoSin interacción

    Concomitant use with digoxin did not affect the pharmacokinetics of either drug. (etiqueta de Trospio, Interacciones medicamentosas)

  • Zaleplónsedante-hipnóticoSin interacción

    Drugs with a Narrow Therapeutic Index Digoxin: Zaleplon (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days). (etiqueta de Zaleplón, Interacciones medicamentosas)

Compruebe Digoxina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.